[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue].

By W. Remmele, H. Stegner. 1987

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Immunohistochemical Analysis of Potential Therapeutic Targets PRAME, FOLR1, and CLDN18.2 in Salivary Gland Carcinomas (2026, unknown): “A semiquantitative immunohistochemical analysis was conducted using the Immunoreactivity Score (IRS) as described by Remmele and Stegner (1987) [27].”
Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas (2026, unknown): “Additionally, stained slides were semiquantitatively assessed using the IRS according to Remmele and Stegner [16].”
Prognostic impact of intra- and peritumoral immune cell subpopulations in head and neck squamous cell carcinomas – comprehensive analysis of the TCGA-HNSC cohort and immunohistochemical validation on 101 patients (2023, methodology): “The stained slides were semiquantitatively assessed by a modified immune reactive score according to Remmele and Stegner (22).”
Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation (2023, methodology): “SEC62-immunoreactivity was evaluated using the well-established immunoreactive score (IRS) by Remmele and Stegner [35] with IRS values ranging from a minimum of 0 (weak) to a maximum of 12 (strong).”